Notably, hypermethylation and silencing of tumor suppressor gene promoters, like MLH1 in various cancers, may drive tumor growth and serve as potential early indicators for diagnosis or response to therapy, assessing PD‐L1 expression levels is also essential for determining candidacy for immunotherapy [12, 13]. The gene discussed is CD274; the disease is cancer.